Bringing clinical trial opportunities to community oncology
Clinical trials for oncology drugs in the community setting is an integral component of OPN’s comprehensive platform for cancer care. By coordinating access to these clinical trial opportunities, OPN is able to offer its patients the ability to participate in leading edge clinical research normally limited to a restricted population. By giving community oncology patients access to these trials, OPN will expand access to new and innovative therapies for many underserved communities, and ensure patients receive off-labeled treatments in an IRB-approved, safe and protected environment.
If you have any questions regarding the studies listed below, please contact Heather Lyon at 818.254.2526 or by email.
To view the full trial description please click on the NCT number for the particular trial.
| Diagnosis | Protocol Title | Patient Population | Key Inclusion | Key Exclusion | NCT Number |
|---|---|---|---|---|---|
| Brain | An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors. | Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis | -Stable or decreasing steroids 5 days prior to consent -Progression within 90 day must be outside radiation field or provonsenten by Bx/resection -Seizures must be controlled for 14 days prior to ICF | - Various previous Tx requirements - XRT of CNS lesions within 14 days before first dose - History of known lepomeningeal involvement | NCT06047379 |
| Breast | ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)-STML-ELA-0322 | Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer | - Chemotherapy naïve - 1 or 2 prior homonal therapies and no prior CDK4/6 inhibitor in the metastatic setting | - Prior chemotherapy or CDK4/6 inhibitor in the metastatic setting | NCT05596409 |
| Breast | A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE)-STML-ELA-0222 | Estrogen Receptor Positive, HER-2 Negative, Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor | - Multi-arm umbrella study - Chemotherapy naïve and 1 or 2 prior hormonal therapies in the metastatic setting, one of which was in combination with CDK4/6 inhibitor (except for Arm D). PIK3CA mutation + required for Arm A. | - Prior chemotherapy in met. setting * Arm A: Prior Tx with alpelisib or PI3K inhibitor. Prior h/o T1DM or uncontrolled T2DM * Arm B: Prior Tx with everolimus * Arm C: Prior Tx with Abemaciclib * Arm D: Prior Tx with CDK4/6 inhibitor | NCT05563220 |
| Lung | A Phase III, Open-label, Randomized, Active Controlled, Trial Evaluating Orally Administered BI 1810631 Compared with standard of Care as First-line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Harbouring HER2 Tyrosine Kinase Domain Mutations | Not previously treated Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Harbouring HER2 Tyrosine Kinase Domain Mutations | -Documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain per local lab -No previous treatment for locally advanced or metastatic disease -Eligible to receive platinum-based doublet and pembrolizumab -Archieve tissue availabe for central testing | -Tumors with targetable alterations with apporoved available therapy | NCT06151574 |
| Lung | Phase 3, Open-label study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison with Atezolizumab Plus Chemotherapy in Previously Untreated Patients with Extensive-Etage SCLC-HLX10-005-SCLC301 | Newly diagnosed Extensive Stage Small Cell Lung Cancer | - No prior systemic therapy for ES-SCLC. - Patients who received chemoradiotherapy for previous limited stage SCLC must be treated and have a treatment-free interval of at least 6 months | -Symptomatic brain metastasis | NCT05468489 |
| Lung | A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer-HLX10-020-SCLC302 | Newly diagnosed Limited Stage Small Cell Lung Cancer | - Diagnosed with Stage I-III Limited-stage SCLC - Patients who have not previously received systematic treatments for SCLC, including but not limited to radiotherapy, chemotherapy, and immunotherapy. - Patients must provide tumor tissues that meet the requirements for assay of PD-L1 expression level. Patients are assessed for an evaluable PD-L1 expression category | - The subject has not previously received antibodies/drugs against immune checkpoints such as PD-1, PD-L1, CTLA4 | NCT05353257 |
| Lung | A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation-DZ2022E0005 | Stage IIIb-IV Metastatic NSCLC with EGFR Exon 20 insertion mutation. | - Metastatic NSCLC with EGFR Exon 20 insertion mutation. - Newly diagnosed or have not received prior systemic treatment for locally advanced or metastatic NSCLC. | - Prior treatment for locally advanced or metastatic and NSCLC | NCT05668988 |
| Lung | An Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR or Exon 19 deletion Mutations Only) | Locally Advanced or Metastatic NSCLC (Uncommon EGFR or Exon 19 deletion Mutations Only) | - Biopsy proven Locally advanced/metastatic NSCLC with 1) COHORT 1-primary uncommon EGFR mutations and ≤ 1 prior line of chemotherapy or immunotherapy OR 2) COHORT 2-acquired uncommon EGFR mutations with disease progression on while on continuous treatment with EGFR TKI-additional lines of chemotherapy or immunotherapy may have been given | - COHORT 1 - any prior EGFR TKI therapy - COHORT 2- prior second-generation EGFR TKI (e.g. afatinib or dacomitinib) | NCT06010329 |
| Lung | An Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR or Exon 19 deletion Mutations Only) | Locally Advanced or Metastatic NSCLC harboring a non-resistant uncommon EGFR mutation | ≤ 1 prior line of chemotherapy | - Prior Tx with EGFR TKI | NCT05168566 |
| Pancreatic | A Single Arm Study Evaluating the Tolerability and Markers of Pancreatic Cancer with a Specially Designed Medical Food Restricted in Specific AminoAcids for Subjects with Metastatic Pancreatic Adenocarcinoma Being Treated with First-line Gemcitabine+nab Paclitaxel-NEAAR-001 | Newly Diagnosed Metastatic Pancreatic Cancer | - Planned for SOC gemzar/abraxane | - Prior Tx | NCT05078775 |